TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

14 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

14 Dec 2021 06:15:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting

10 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Regulatory Update

30 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Jefferies London Healthcare Conference

15 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 08:34:14 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

04 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update

01 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

14 Oct 2021 09:45:00 By Nasdaq GlobeNewswire

TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

30 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

29 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

23 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

23 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

20 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

13 Sep 2021 08:21:06 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

30 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

02 Aug 2021 06:00:00 By Nasdaq GlobeNewswire